RT Journal Article
SR Electronic
T1 Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 57
OP 62
DO 10.21873/invivo.12676
VO 36
IS 1
A1 TURNER, MICHAEL A.
A1 HOLLANDSWORTH, HANNAH M.
A1 NISHINO, HIROTO
A1 AMIRFAKHRI, SIAMAK
A1 LWIN, THINZAR M.
A1 LOWY, ANDREW M.
A1 KAUR, SUKHWINDER
A1 NATARAJAN, GOPALAKRISHNAN
A1 MALLYA, KAVITA
A1 HOFFMAN, ROBERT M.
A1 BATRA, SURINDER K.
A1 BOUVET, MICHAEL
YR 2022
UL http://iv.iiarjournals.org/content/36/1/57.abstract
AB Background: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. Results: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). Conclusion: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.